Oppenheimer set a $28.00 target price on Syros Pharmaceuticals (NASDAQ:SYRS) in a research report sent to investors on Wednesday morning. The brokerage currently has a buy rating on the stock.

Several other equities analysts also recently commented on SYRS. Cann reissued a buy rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. ValuEngine downgraded shares of Syros Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 22nd. JMP Securities raised shares of Syros Pharmaceuticals from a market perform rating to an outperform rating and set a $33.00 target price on the stock in a research report on Thursday, September 28th. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 11th. Finally, Roth Capital initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, October 23rd. They set a neutral rating and a $15.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $26.14.

Syros Pharmaceuticals (NASDAQ:SYRS) traded down $0.44 during trading on Wednesday, reaching $9.08. 663,800 shares of the company’s stock traded hands, compared to its average volume of 132,761. Syros Pharmaceuticals has a 52-week low of $6.30 and a 52-week high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). equities analysts anticipate that Syros Pharmaceuticals will post -2.1 EPS for the current fiscal year.

Several large investors have recently modified their holdings of SYRS. FMR LLC grew its position in shares of Syros Pharmaceuticals by 11.9% in the second quarter. FMR LLC now owns 3,926,998 shares of the company’s stock valued at $63,185,000 after purchasing an additional 418,061 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Syros Pharmaceuticals by 189.6% in the second quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after purchasing an additional 250,507 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in shares of Syros Pharmaceuticals in the third quarter valued at about $1,766,000. State Street Corp grew its position in shares of Syros Pharmaceuticals by 176.7% in the second quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after purchasing an additional 108,250 shares during the last quarter. Finally, AWM Investment Company Inc. grew its position in shares of Syros Pharmaceuticals by 155.8% in the second quarter. AWM Investment Company Inc. now owns 121,624 shares of the company’s stock valued at $1,957,000 after purchasing an additional 74,074 shares during the last quarter. 58.02% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/12/14/syros-pharmaceuticals-syrs-given-a-28-00-price-target-at-oppenheimer.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.